Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | AHCY | P23526 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410858 | 0.89 | YTHDC1 (0.60) | YTHDC1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL29318369 | 0.88 | YTHDC1 (0.59) | YTHDC1ADORA3AHCY | |
| SCHEMBL2041441 | 0.88 | YTHDC1 (0.59) | YTHDC1ADORA3AHCY | |
| SCHEMBL21082466 | 0.86 | YTHDC1 (0.56) | YTHDC1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL21138875 | 0.86 | YTHDC1 (0.56) | YTHDC1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL23584826 | 0.85 | YTHDC1 (0.55) | YTHDC1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL20711187 | 0.81 | PI4KA (0.57) | ADORA3ADORA2AADORA2BADORA1AHCY | |
| SCHEMBL22524035 | 0.81 | YTHDC1 (0.50) | YTHDC1ADORA3ADORA2AADORA2BADORA1 | |
| Phenol SCHEMBL27699602 | 0.81 | ABL1 (0.52) | YTHDC1ADORA3 | |
| SCHEMBL20324865 | 0.81 | P2RY1 (0.59) | YTHDC1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020205323-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-10-08 | — | — | WO | disclosed |